Even positive oncology trial results can face FDA scrutiny if they do not show applicability across patient populations
Why Global Oncology Evidence May Not Support U.S. Regulatory Approval
Harpreet Singh, MD
Even positive oncology trial results can face FDA scrutiny if they do not show applicability across patient populations